- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05520788
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing (CCGLC-006)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to explore the precise treatment in hepatobiliary cancer patients and evaluate drug efficacy, progression free and overall survival. This trial study is based on genetic tests, then therapeutic target drugs are administered according to the genetic test reports. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit from precise treatment which targets particular genetic abnormality. The identifications of these genetic abnormalities may help treat hepatobiliary cancer patients.
The genetic tests are performed for the eligible subjects in this study, then therapeutic target drugs are administered according to the genetic test reports. While the precise treatments, follow-ups are conducted to evaluate the efficacy and safety of the target drugs for the subjects, until the overall survival.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Bixiang Zhang, PhD
- Phone Number: 86-027-83665293
- Email: bixiangzhang@hust.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Recruiting
- Hepatic Surgery Center, Tongji Hospital, Huazhong University of Science and Technology
-
Contact:
- Ze-yang Ding, M.D.
- Phone Number: +8613407156200
- Email: dingzyang@sina.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age from 18 to 65, male or female.
- Radiologically and pathologically confirmed as hepatobiliary cancers with stage IV.
- Palliative care as the preferred.
- The result of next-generation sequencing (NGS) test show the patient has gene mutation and also can be treated by the right commercial products that have been approved by the China Food and Drug Administration (CFDA) or the Food and Drug Administration (FDA).
- ECOG performance status 0-2.
- Life expectancy ≥3 months.
- Agree to sign informed consent form.
Exclusion Criteria:
- Hepatobiliary cancer patient with stageI-III, or with any of the following items will not be eligible for screening. Such as, suitable for the treatment of radical resection, radical resection but evaluation unmeasurable.
- The result of NGS test show the patient has no gene mutation, or has gene mutation but no medicine.
- ECOG performance status ≥ 3.
- Female patients who are pregnant or not using a contraceptive method of birth control.
- History or presence of serious cardiovascular or cerebrovascular abnormalities.
- Abnormalities of the hepatic or renal functions, such as jaundice, ascites, bilirubin ≥ 1.5×ULN, alkaline phosphatase ≥ 3×ULN, persistent protein urine≥ grade 3 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTC-AE] v4.0), creatinine ratio > 3.5g/24 hours, renal failure.
- Persistent infection > grade 2 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTC-AE] v4.0).
- Patient has underwent a major operation 4 weeks prior to screening or has not yet recovered from the operation.
- Patient with epilepsy, known or untreated brain metastases.
- The presence of wounds, ulcers or fractures that can not be healed, or with a past history of transplantation.
- The presence of bleeding events ≥grade 3 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTC-AE] v4.0) , present evidence or past history of coagulation dysfunction disorders.
- Known human immunodeficiency virus (HIV) infection history.
- Patient with drug abuse or unstable compliance.
- The presence of unresolved toxicity caused by any previous treatment/operation > grade 1 (according to National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTC-AE] v4.0), except alopecia, anemia or hypothyroidism).
- Investigator consider that the patient should not be enrolled in this study by careful assessment.
- The subjects participate in any other clinical trial in the meantime.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Precise medicine
All patients should accept next-generation sequencing (NGS) test before treatment.
|
During screening stage, all patients should accept next-generation sequencing (NGS) test.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: From treatment initiation for advanced or metastatic HCC to the first date of disease progression for any cause up to 2 year
|
Time of progression will be obtained by telephone interview or medical treatment records.
|
From treatment initiation for advanced or metastatic HCC to the first date of disease progression for any cause up to 2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate (DCR)
Time Frame: From treatment initiation to SD, CR or PR, up to 2 years
|
The proportion of patients who had either stable disease (SD) for ≥ 6 months, a CR or PR after initiation of treatment for HCC
|
From treatment initiation to SD, CR or PR, up to 2 years
|
Overall Survival (OS)
Time Frame: 2 years
|
Include all-cause death of patients in this study.
|
2 years
|
Objective response rates (ORR)
Time Frame: From treatment initiation to CR or PR, up to 2 years
|
Percentage of patients whose tumors have a complete or partial response to treatment.
|
From treatment initiation to CR or PR, up to 2 years
|
Duration of Response (DOR)
Time Frame: From treatment initiation to PD, up to 2 years
|
duration from the first assessment of the tumor was CR or PR to the time that the first assessment for PD or date of death from any cause
|
From treatment initiation to PD, up to 2 years
|
Adverse Drug Reaction (ADR)/Adverse Event (AE)
Time Frame: Through study completion, an average of 2 years.
|
Patients with treatment-related adverse events as assessed by CTCAE v4.0.
|
Through study completion, an average of 2 years.
|
Quality of Life (QoL) after treatment
Time Frame: Through study completion, an average of 2 years.
|
The life quality of every subject will be assessed every 3 months according to the FACT-Hep questionnaire, which assesses generic HRQL concerns and disease-specific issues.
|
Through study completion, an average of 2 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Wanguang Zhang, Tongji Hospital
- Principal Investigator: Zeyang Ding, Tongji Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJ-IRB20220129
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCActive, not recruitingAdvanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...United States
-
Roswell Park Cancer InstituteNational Comprehensive Cancer NetworkCompletedAdvanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | BCLC Stage C Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC... and other conditionsUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI); Genentech, Inc.RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedUnresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingUnresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAdvanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular CarcinomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)CompletedStage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular CarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; American Society of Clinical Oncology; Radiological... and other collaboratorsWithdrawnHepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Stage... and other conditionsUnited States
Clinical Trials on precise medicine
-
Bispebjerg HospitalHolbaek Sygehus; University of Zealand HospitalNot yet recruitingPregnancy Complications | Preterm Birth | Pregnancy Related | Small for Gestational Age at DeliveryDenmark
-
Beijing Tsinghua Chang Gung HospitalRecruitingPain, Chronic | Pain, IntractableChina
-
Maastricht University Medical CenterCatharina Ziekenhuis Eindhoven; Universitair Ziekenhuis Brussel; General Hospital... and other collaboratorsCompletedCritical Illness | Intensive Care Unit Acquired WeaknessBelgium, Netherlands
-
The Netherlands Cancer InstituteUnknown
-
Peking Union Medical College HospitalCompletedTransverse Facial Cleft
-
China-Japan Friendship HospitalRecruiting
-
Seoul St. Mary's HospitalUnknownThyroid CancerKorea, Republic of
-
Sun Yat-sen UniversityCompletedHepatocellular Carcinoma(HCC) | Cirrhotic Portal HypertensionChina
-
Xin Jiang, MDUnknown
-
Assiut UniversityNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)